This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 15.46% and 2.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More
by Zacks Equity Research
Healthcare stocks like HUM, AMED, CRL, TDOC and PRAH are likely to benefit from higher membership and revenues in the second quarter.
Cigna (CI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) Q2 earnings should reflect increase in revenues from growth across its segments and share buyback.
Why Earnings Season Could Be Great for Humana (HUM)
by Zacks Equity Research
Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Molina Healthcare (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter earnings are likely to be cushioned by its strategic divestitures as well as cost-reduction plans, partly offset by lower revenues.
Is a Beat in the Cards for Humana's (HUM) Earnings in Q2?
by Zacks Equity Research
Humana's (HUM) second-quarter earnings are likely to gain traction from a solid revenue stream.
What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 earnings are likely to be aided by higher admissions and revenues, partly offset by escalating expenses.
WellCare Health's (WCG) Q2 Earnings: What's in Store?
by Zacks Equity Research
WellCare Health's (WCG) Q2 earnings are likely to be supported by higher membership.
Anthem's (ANTM) Q2 Earnings Beat Estimates, Increase Y/Y
by Zacks Equity Research
Anthem's (ANTM) second-quarter earnings gain from higher revenues.
Humana (HUM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Koninklijke Philips' (PHG) Q2 Earnings & Sales Rise Y/Y
by Zacks Equity Research
Koninklijke Philips' (PHG) second-quarter results benefit from robust performance in the Diagnosis & Treatment business.
Centene's (CNC) Q2 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Centene's (CNC) second-quarter earnings benefit from higher revenues and operational efficiency.
What to Expect for Universal Health's (UHS) Q2 Earnings
by Zacks Equity Research
Universal Health's (UHS) Q2 earnings are likely to gain from its strong segmental performances at Acute Care and Behavioral Health, partly offset by high costs.
What's in the Offing for Anthem's (ANTM) Earnings in Q2?
by Zacks Equity Research
Anthem's (ANTM) second-quarter earnings are likely to benefit from a solid revenue stream.
The Zacks Analyst Blog Highlights: Cisco, Home Depot, Merck, Humana and Public Service Enterprise
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco, Home Depot, Merck, Humana and Public Service Enterprise
Top Stock Reports for Cisco, Home Depot & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Home Depot (HD) and Merck (MRK).
Cigna Stock Gains Near 9% on Drug Rebate Proposal Pullback
by Zacks Equity Research
Cigna's (CI) Pharmacy Benefits management is poised to gain due to the pullback of the drug rebate proposal.
Why the Earnings Surprise Streak Could Continue for Humana (HUM)
by Zacks Equity Research
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Health Insurers Rejoice on Pullback of Drug Rebate Plan
by Sapna Bagaria
After many regulatory disturbances and overhang of the drug rebate ban proposal, a repeal of it is a breather for health insurers.
Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play
by Christopher Vargas
The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.
Tenet Healthcare Inks Deal to Offer Quality Health Services
by Zacks Equity Research
Tenet Healthcare (THC) enters into a contract with Aetna owing to which the company's healthcare services can be availed by Aetna members.
Healthcare Tumbles on Trump's Price Disclosure Order
by Sapna Bagaria
Hospital and health insurers' lose on Trump's executive order to unveil price of services to patients.
The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon
Top Stock Reports for Union Pacific, NextEra & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), NextEra (NEE) and Biogen (BIIB).
Why Is Humana (HUM) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.